Qlucore, a developer of bioinformatics software, has announced a three year license contract with Actelion, one of Europe’s leading biopharmaceutical companies.
Actelion focuses on the science and medicine of pulmonary arterial hypertension (PAH), and its understanding of the complex pathways and molecular mechanisms of this disease has enabled the development of tailored medicines that can make a real difference to patient outcomes.
With more than 15 years of experience, Actelion’s Drug Discovery group, based in Allschwil, Switzerland, combines state-of-the-art technology with human expertise and teamwork. Scientists use an inquisitive drug hunting approach to discover and develop novel medicines to improve patients' lives. Actelion has more than 100 medicinal and process chemists creating low molecular weight compounds which go through a cyclical drug discovery process for optimisation. These innovative compounds are then characterised by molecular biologists and biochemists in relation to the chosen molecular drug targets.
Actelion has been using Qlucore Omics Explorer for exploration and analysis of large data sets, mainly within Translation Science, since 2011. Qlucore Omics Explorer features the latest data visualisation techniques and presentation technologies which enable researchers to examine enormous quantities of data, to test different hypothesis much more quickly, and to explore alternative scenarios within seconds, all without having to rely exclusively on the help of specialist bioinformaticians and biostatisticians.
Biologists within Actelion’s research organisations have become more active in data analysis and exploration by using Qlucore Omics Explorer. Actelion plans to increase its use of Qlucore’s software and extend to more research teams by placing this three year license order.
